Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 10,628 matching trials from the live ClinicalTrials.gov search.

Filters: Pittsburgh, Pennsylvania Clear all

Conditions: Neoplasms
Interventions: Rogaratinib (BAY1163877) oral solution, Rogaratinib (BAY1163877) oral tablet, Rogaratinib (BAY1163877) 800 mg BID; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 3
States / cities: Chicago, Illinois • Pittsburgh, Pennsylvania

Conditions: Graft Versus Host Disease
Interventions: cyclosporine, hydroxychloroquine, prednisone, tacrolimus; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 29 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 89
States / cities: Tucson, Arizona • Little Rock, Arkansas • Downey, California + 67 more

Conditions: Infection, Candida, Non Albicans Species
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: Not listed
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Sickle Cell Disease, Depression, Anxiety
Interventions: off-the-shelf digital CBT, adapted digital CBT; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 16 Years to 35 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cystic Fibrosis
Interventions: hypertonic saline (7%), isotonic saline; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Polymyositis, Dermatomyositis, Autoimmune Necrotizing Myopathy, Overlap Myositis, Juvenile Myositis Above the Age of 18
Interventions: Abatacept subcutaneous, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 25
States / cities: Phoenix, Arizona • Beverly Hills, California • Orange, California + 22 more

Conditions: Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer
Interventions: ChemoID Assay, Standard Chemotherapy; Diagnostic Test · Drug
Lead sponsor: Cordgenics, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 8
States / cities: Los Angeles, California • Miami, Florida • New Orleans, Louisiana + 5 more

Conditions: Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases, Genetic Disease
Interventions: DCR-PHXC, Sterile Normal Saline (0.9% NaCl); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 6 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: San Francisco, California • Boston, Massachusetts • Rochester, Minnesota + 2 more

Conditions: Obese, Pregnancy, Sleep Disordered Breathing
Interventions: CPAP, sham-CPAP, Sleep hygiene; Device · Other
Lead sponsor: Francesca Facco, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Dissociation
Interventions: Vibration, Breath Focus, No Distractions; Device · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia • Pittsburgh, Pennsylvania

Conditions: Primary Invasive Breast Cancer
Interventions: Observational; Other
Lead sponsor: Myriad Genetic Laboratories, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 855 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 52
States / cities: Burbank, California • Roseville, California • Fort Myers, Florida + 40 more

Conditions: Lung Injury, Acute
Interventions: SB-681323 Intravenous 3mg, SB-681323 Intravenous 7.5 mg, SB-681323 Intravenous 7.5mg, SB-681323 Intravenous 10mg, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: Lexington, Kentucky • Durham, North Carolina • Winston-Salem, North Carolina + 3 more

Conditions: Strategy Training
Interventions: Strategy Training; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Advanced Cancer
Interventions: BMS-986258, Nivolumab, rHuPH20; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 10
States / cities: Los Angeles, California • Aurora, Colorado • Iowa City, Iowa + 6 more

Conditions: Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN
Interventions: MEDI4736, MEDI4736 + Tremelimumab, Standard of Care; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 96 Years
Enrollment: 736 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 23
States / cities: Tucson, Arizona • Fullerton, California • Los Angeles, California + 18 more

Conditions: Kidney Diseases, Cardiovascular Diseases
Interventions: Commercially available Diindolylmethane, Placebo; Dietary Supplement · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 75 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
Interventions: Durvalumab, Standard Chemotherapy, Ipilimumab and Nivolumab; Drug
Lead sponsor: PrECOG, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 25
States / cities: La Jolla, California • Miami, Florida • Tampa, Florida + 20 more

Conditions: Monkeypox
Interventions: JYNNEOS; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 50 Years
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 17
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 13 more

Conditions: Postoperative Pain, Opioid Dependence
Interventions: Oxycodone; Drug
Lead sponsor: Senthil Sadhasivam; Other
Eligibility: 8 Years to 18 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Indianapolis, Indiana • Pittsburgh, Pennsylvania

Conditions: Venous Thromboembolism
Interventions: Semuloparin Sodium, Enoxaparin sodium, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 4,413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 25
States / cities: Birmingham, Alabama • Corlton, California • Huntingdon Beach, California + 18 more

Conditions: Panic Disorder, Anxiety Disorder
Interventions: Telephone-based collaborative care management; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Infant Behavior, Child Behavior, Parenting, Child Rearing, Depression, Personal Satisfaction, Behavioral Symptoms, Social Control, Informal
Interventions: Video Interaction Project, Family Check Up; Behavioral
Lead sponsor: New York University; Other
Eligibility: 0 Years and older
Enrollment: 403 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2025
U.S. locations: 2
States / cities: New York, New York • Pittsburgh, Pennsylvania

Conditions: Varicose Veins
Interventions: polidocanol injectable foam, 0.125%, polidocanol injectable foam, 0.5%, polidocanol injectable foam, 1.0%, Vehicle; Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 12
States / cities: Dothan, Alabama • San Diego, California • Lafayette, Indiana + 8 more

Conditions: Hepatitis B
Interventions: GSK3228836, Placebo, Nucleos(t)ide therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Los Angeles, California • Miami, Florida • Decatur, Georgia + 4 more

Search by objective public record fields.

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease

Changing Patterns of Candida Infections in Urban Medical Centers

Designing an Implementation Strategy for Delivering Routine Mental Health Screening and Treatment

Absorptive Clearance After Inhaled Osmotics in Cystic Fibrosis

Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy

Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer

A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2

Sleep Disordered Breathing, Obesity and Pregnancy Study (SOAP)

Mechanistic Interventions and Neuroscience of Dissociation

EndoPredict® Extended Endocrine Trial (EXET)

SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS

Strategy Training for People With Aphasia After Stroke

An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer

Targeting FMO-Mediated TMAO Formation in Kidney Disease (TMAO) Study

DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox

PG and PK of Oxycodone to Personalize Post-op Pain Management Following Surgery in Children

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

Improving Quality of Primary Care for Patients With Anxiety and/or Panic Disorders

Integrated Model for Promoting Parenting and Early School Readiness in Pediatrics

Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence

A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)